Table 1.
Patient and donor characteristics (n = 202).
| Characteristic | All patients | MSDT | Haplo-SCT | ||||
|---|---|---|---|---|---|---|---|
| MRD neg | MRD pos | P-value | MRD neg | MRD pos | P-value | ||
| Number of patients | 202 | 48 | 13 | 100 | 41 | ||
| Median age (range), years | 32 (4–63) | 40 (7–63) | 38 (8–60) | 0.828 | 27 (4–57) | 32 (11–53) | 0.368 |
| Male, n (%) | 117 (57.9%) | 23 (47.9%) | 6 (46.2%) | 0.910 | 60 (60.0%) | 28 (68.3%) | 0.356 |
| Disease status, n (%) | 0.006 | 0.003 | |||||
| CR1 | 188 (93.1%) | 47 (97.9%) | 9 (69.2%) | 98 (98.0%) | 34 (82.9%) | ||
| CR2 | 13 (6.9%) | 1 (2.1%) | 4 (30.8%) | 2 (2.0%) | 6 (14.7%) | ||
| CR > 2 | 1 (0.5%) | 0 | 0 | 0 | 1 (2.4%) | ||
| IKZF, n (%) | 0.409 | 0.890 | |||||
| Positive | 49 (24.3%) | 9 (18.8%) | 4 (30.8%) | 20 (20.0%) | 16 (39.0%) | ||
| Negative | 57 (28.2%) | 9 (18.8%) | 3 (23.1%) | 35 (35.0%) | 10 (24.4%) | ||
| Unknown | 96 (47.5%) | 30 (62.5%) | 6 (46.2%) | 45 (45.0%) | 15 (36.6%) | ||
| Cytogenetic subgroup of ALL, n (%) | 1.000 | 0.770 | |||||
| t(9;22) | 136 (67.3%) | 35 (72.9%) | 9 (69.2%) | 66 (66.0%) | 26 (63.4%) | ||
| t(9;22) with other karyotypic abnormalities | 66 (32.7%) | 13 (27.1%) | 4 (30.8%) | 34 (34.0%) | 15 (36.6%) | ||
| WBC at diagnosis, n (%) | 0.850 | 0.254 | |||||
| High | 98 (48.5%) | 16 (33.3%) | 5 (38.4%) | 53 (53.0%) | 24 (58.5%) | ||
| Normal | 79 (39.1%) | 28 (58.3%) | 7 (53.9%) | 30 (30.0%) | 14 (34.1%) | ||
| Unknown | 25 (12.4%) | 4 (8.4%) | 1 (7.7%) | 17 (17.0%) | 3 (7.3%) | ||
| Levels of pre–transplant MRD, median (range) | 0.03% (0.001–2.210%) | 0.03% (0.001–0.760%) | 0.03% (0.001–2.210%) | 0.670 | |||
| Donor-recipient sex-matched grafts, n (%) | 0.731 | 0.320 | |||||
| Male-male | 47 (23.3%) | 12 (25.0%) | 2 (15.4%) | 20 (20.0%) | 13 (31.7%) | ||
| Male-female | 35 (17.3%) | 13 (27.1%) | 5 (38.5%) | 13 (13.0%) | 4 (9.8%) | ||
| Female-male | 71 (35.1%) | 12 (25.0%) | 4 (30.8%) | 40 (40.0%) | 15 (36.6%) | ||
| Female-female | 49 (24.3%) | 11 (22.9%) | 2 (15.4%) | 27 (27.0%) | 9 (22.0%) | ||
| Donor-recipient relationship, n (%) | 0.600 | 0.649 | |||||
| Father-child | 47 (23.3%) | 0 | 0 | 35 (35.0%) | 12 (29.3%) | ||
| Mother-child | 15 (7.4%) | 0 | 0 | 10 (10.0%) | 5 (12.2%) | ||
| Sibling-sibling | 105 (52.0%) | 47 (97.9%) | 13 (100%) | 34 (34.0%) | 11 (26.8%) | ||
| Child-parent | 30 (14.9%) | 0 | 0 | 19 (19.0%) | 11 (26.8%) | ||
| Other | 5 (2.5%) | 1 (2.1%) | 0 | 2 (2.0%) | 2 (4.9%) | ||
| ABO matched graft, n (%) | 0.657 | 0.153 | |||||
| Matched | 117 (57.9%) | 31 (64.6%) | 10 (76.9%) | 57 (57.0%) | 19 (46.3%) | ||
| Major mismatch | 45 (22.3%) | 8 (16.7%) | 2 (15.4%) | 20 (20.0%) | 15 (36.6%) | ||
| Minor mismatch | 30 (14.9%) | 7 (14.6%) | 1 (7.7%) | 18 (18.0%) | 4 (9.8%) | ||
| Bi-directional mismatch | 10 (5.0%) | 2 (4.2%) | 0 | 5 (5.0%) | 3 (7.3%) | ||
| Cell compositions in allografts | |||||||
| Infused nuclear cells, (range) 108/kg | 8.02 (2.53–13.14) | 7.57 (2.53–13.14) | 7.99 (5.75–11.41) | 0.467 | 8.22 (4.92–12.06) | 8.12 (5.89–11.94) | 0.404 |
| Infused CD34+ cells, (range) 106/kg | 2.82 (0.59–8.51) | 2.77 (0.59–8.51) | 2.54 (0.59–8.51) | 0.664 | 2.82 (0.62–6.67) | 2.96 (0.84–7.20) | 0.108 |
| DLI after transplant, n (%) | 1.000 | 0.205 | |||||
| For relapse prophylaxis and intervention | 7 (31.8%) | 1 (20.0%) | 2 (40.0%) | 4 (57.1%) | 0 | ||
| For relapse treatment | 15 (68.2%) | 4 (80.0%) | 3 (60.0%) | 3 (42.9%) | 5 (100%) | ||
| Pre-transplantation TKI | 0.012 | 0.138 | |||||
| Imatinib | 163 (80.7%) | 44 (91.7%) | 8 (61.5%) | 82 (82.0%) | 29 (70.7%) | ||
| Others | 39 (19.3%) | 4 (8.3%) | 5 (38.5%) | 18 (18.0%) | 12 (29.3%) | ||
| Post-transplantation TKI | 0.004 | 0.069 | |||||
| Imatinib | 178 (88.1%) | 44 (91.7%) | 7 (53.8%) | 93 (93.0%) | 34 (82.9%) | ||
| Others | 24 (11.9%) | 4 (8.3%) | 6 (46.2%) | 7 (7.0%) | 7 (17.1%) | ||
| Median courses of chemotherapy | 4 (1–16) | 3 (2–9) | 5 (2–16) | 0.055 | 4 (1–11) | 4 (2–15) | 0.480 |
HLA, human leukocyte antigen; MSDT, vHLA-matched sibling donor transplantation; Haplo-SCT, unmanipulated haploidentical stem cell transplantation; MRD, minimal residual disease; neg, negative, pos, positive; CR, complete remission; DLI, donor lymphocyte infusions; TKI, tyrosine kinase inhibitor.